Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
| Market Capitalization | $72.0156 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.031 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.03 |
| EBITDA | -9,925.147 |
| Profit Margin | -1.4726 |
| Operating Margin TTM | -2.4228 |
| Return on Assets TTM | -0.1904 |
| Return on Equity TTM | -0.7784 |
| Revenue TTM | 4,243.069 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2010-06-30 | 362 | 65 | ||
| 2011-06-30 | 798 | 266 | ||
| 2012-06-30 | 458 | 324 | ||
| 2013-06-30 | 524 | 438 | ||
| 2014-06-30 | 691.405 | 597.151 | 94.254 | 3,437.703 |
| 2015-06-30 | 790.43 | 652.856 | 137.574 | 5,997.343 |
| 2016-06-30 | 666.499 | 497.589 | 168.91 | 6,082.442 |
| 2017-06-30 | 529.818 | 438.137 | 91.681 | 6,763.865 |
| 2018-06-30 | 619.179 | 469.886 | 149.293 | 8,635.394 |
| 2019-06-30 | 1,087.353 | 732.335 | 355.018 | 9,106.131 |
| 2020-06-30 | 719.523 | 505.374 | 214.149 | 9,729.562 |
| 2021-06-30 | 1,017.962 | 625.645 | 392.317 | 12,497.264 |
| 2022-06-30 | 1,531.718 | 702.61 | 829.108 | 12,702.334 |
| 2023-06-30 | 4,243.069 | 1,026.155 | 3,216.914 | 14,111.587 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2010-06-30 | 212 | 1,517 | 205 | 1,914 | ||
| 2011-06-30 | 559 | 1,909 | 343 | 3,090 | ||
| 2013-06-30 | 591 | 1,765 | 1,551 | 3,163 | ||
| 2014-06-30 | 8,185.297 | 9,571.252 | 1,667.134 | 15,250.567 | ||
| 2015-06-30 | 4,774.108 | 6,536.133 | 2,152.343 | 15,302.482 | ||
| 2016-06-30 | 5,181.812 | 7,113.184 | 2,228.587 | 19,359.578 | ||
| 2017-06-30 | 5,046.257 | 7,158.896 | 2,446.409 | 0 | 23,102.888 | |
| 2018-06-30 | 2,910.233 | 5,229.864 | 2,857.662 | 0 | 25,984.676 | |
| 2019-06-30 | 11,236.299 | 13,597.69 | 2,873.228 | 0 | 39,026.963 | |
| 2020-06-30 | 20,441.616 | 23,170.571 | 2,267.09 | 107.63 | 53,674.762 | |
| 2021-06-30 | 16,328.913 | 19,330.414 | 2,456.057 | 114.158 | 55,776.179 | |
| 2022-06-30 | 11,021.552 | 37,895.706 | 27,991.072 | 120.022 | 57,476.08 | |
| 2023-06-30 | 24,817.962 | 29,605.483 | 23,456.53 | 180.629 | 57,897.993 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2010-06-30 | ||||||
| 2011-06-30 | ||||||
| 2013-06-30 | 591.144 | |||||
| 2014-06-30 | -2,182.185 | -1,753.026 | 2,876.208 | 591.144 | 3,467.352 | |
| 2015-06-30 | -3,742.715 | -2,767.61 | 1,306.756 | 3,467.352 | 4,774.108 | |
| 2016-06-30 | -3,784.864 | -3,321.12 | 407.704 | 4,774.108 | 5,181.812 | |
| 2017-06-30 | -4,177.416 | -3,555.38 | -135.555 | 5,181.812 | 5,046.257 | |
| 2018-06-30 | -5,757.114 | -4,644.252 | -2,136.024 | 5,046.257 | 2,910.233 | |
| 2019-06-30 | -5,852.214 | -4,180.466 | 8,326.066 | 2,910.233 | 11,236.299 | |
| 2020-06-30 | -6,151.029 | -5,256.871 | 9,205.317 | 11,236.299 | 20,441.616 | |
| 2021-06-30 | -9,037.025 | -4,633.33 | -4,112.703 | 20,441.616 | 16,328.913 | |
| 2022-06-30 | -9,106.585 | -8,757.966 | -5,307.361 | 16,328.913 | 11,021.552 | |
| 2023-06-30 | -6,248.181 | 13,796.41 | 11,021.552 | 24,817.962 |